Biblio

Export 5 results:
Author Title [ Type(Desc)] Year
Filters: Author is Ketter, Nzeera  [Clear All Filters]
Journal Article
N. Ketter, H Brashear, R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., and H Arrighi, M., “Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 2, pp. 557-573, 2017.
R. H Brashear, Ketter, N., Bogert, J., Di, J., Salloway, S. P., and Sperling, R., “Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1409-1424, 2018.
S. P. Salloway, Sperling, R., Fox, N. C., Sabbagh, M. N., Honig, L. S., Porsteinsson, A. P., Rofael, H., Ketter, N., Wang, D., Liu, E., Carr, S., Black, R. S., and H Brashear, R., “Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.”, J Alzheimers Dis, vol. 64, no. 3, pp. 689-707, 2018.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.